Pathogenesis of and immunity to melioidosis

Acta Tropica

Volumn 74, Issue 2-3, 2000, Pages 201-210

  Brett, Paul J ^a   Woods, Donald E ^a  

^a Health Sciences Centre Calgary   (Canada)

Author keywords

Burkholderia pseudomallei; Conjugate vaccine; Melioidosis; Pathogenesis; Protective antigens; Virulence factors

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIAL VACCINE; ENDOTOXIN; FLAGELLIN; VIRULENCE FACTOR;

DISEASE PREVALENCE; IMMUNITY; PATHOGEN; VACCINATION;

BACTERIAL VIRULENCE; BACTERIUM ISOLATE; BURKHOLDERIA PSEUDOMALLEI; CONFERENCE PAPER; ENDEMIC DISEASE; HELA CELL; HUMAN; HUMAN CELL; MELIOIDOSIS; NONHUMAN; VACCINE PRODUCTION;

ANTIGENS, BACTERIAL; BACTERIAL VACCINES; BURKHOLDERIA PSEUDOMALLEI; HUMANS; MELIOIDOSIS; VIRULENCE;

EID: 0033959534     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-706X(99)00071-6     Document Type: Conference Paper

References (72)

1. Ashdown L.R., Koehler J.M. Production of hemolysin and other extracellular enzymes by clinical isolates of Pseudomonas pseudomallei. J. Clin. Microbiol. 28:1990;2331-2334.
2. Braley-Mullen H. Antigen requirements for priming of IgG producing B memory cells specific for Type III pneumococcal polysaccharide. Immunology. 40:1980;521-527.
3. Brett P.J., DeShazer D., Woods D.E. Characterization of Burkholderia pseudomallei and Burkholderia pseudomallei-like strains. Epidemiol. Infect. 118:1997;137-148.
4. Brett P.J., DeShazer D., Woods D.E. Burkholderia thailandensis sp. nov., a Burkholderia pseudomallei-like species. Int. J. Syst. Bacteriol. 48:1998;317-320.
5. Brett P.J., Mah D.C., Woods D.E. Isolation and characterization of Pseudomonas pseudomallei flagellin proteins. Infect. Immun. 62:1994;1914-1919.
6. Brett P.J., Woods D.E. Structural and immunologic characterization of Burkholderia pseudomallei O-polysaccharide-flagellin protein conjugates. Infect. Immun. 64:1996;2824-2828.
7. Bryan L.E., Wong S., Woods D.E., Dance D.A.B., Chaowagul W. Passive protection of diabetic rats with antisera specific for the polysaccharide portion of the lipopolysaccharide isolated from Pseudomonas pseudomallei. Can. J. Infect. Dis. 5:1994;170-178.
8. Chaowagul W., White N.J., Dance D.A., Wattanagoon Y., Naigowit P., Davis T.M., Looareesuwan S., Pitakwatchara N. Melioidosis: a major cause of community acquired septicemia in northeastern Thailand. J. Infect. Dis. 159:1989;890-899.
9. Cryz Jr S.J., Sadoff J.C., Furer E., Germanier R. Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans. J. Infect. Dis. 154:1986;682-688.
10. Dance D.A. Melioidosis: the tip of the iceberg? Clinical Microbiol. Rev. 4:1991;52-60.
11. Dance D.A., Wuthiekanun V., White N.J., Chaowagul W. Antibiotic resistance in Pseudomonas pseudomallei. Lancet. 1:1988;994-995.
12. Dance D.A.B. Melioidosis. Rev. Med. Microbiol. 1:1990;143-150.
13. DeShazer, D., Brett, P., Woods, D.E., 1998. The Type II O-antigen moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence. Mol. Microbiol. 30, 1011-1081.
14. DeShazer D., Brett P.J., Carlyon R., Woods D.E. Mutagenesis of Burkholderia pseudomallei with Tn5-OT182: isolation of motility mutants and molecular characterization of the flagellin structural gene. J. Bacteriol. 179:1997;2116-2125.
15. Dintzis R. Rational design of conjugate vaccines. Ped. Res. 32:1992;376-385.
16. Dintzis R.Z., Middleton M.H., Dintiz H.M. Inhibition of anti-DNP antibody formation by high doses of DNP-polysaccharide molecules: effect of hapten density and valence. J. Immunol. 143:1985;423-427.
17. Dintzis R.Z., Middleton M.H., Dintzis H.M. Studies on the immunogenicity and tolerance of T-independant antigens. J. Immunol. 131:1983;2196-2203.
18. Ellison D.W., Baker H.J., Mariappan M. Melioidosis in Malaysia. I. A method for isolation of Pseudomonas pseudomallei from soil and surface water. Am. J. Trop. Med. Hyg. 18:1969;694-697.
19. Esselman M.T., Liu P.V. Lecithinase production by gram-negative bacteria. J. Bacteriol. 81:1961;939-945.
20. Fattom A., Schneerson R., Watson D.C., Karakawa W.W., Fitzgerald D., Pastan I., Li X., Shiloach J., Bryla D.A., Robbins J.B. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus Type 5 and Type 8 capsular polysaccharides and bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect. Immun. 61:1993;1023-1032.
21. Godfrey A.J., Wong S., Dance D.A., Chaowagul W., Bryan L.E. Pseudomonas pseudomallei resistance to beta-lactam antibiotics due to alterations in the chromosomally encoded beta-lactamase. Antimicro. Agents Chemother. 35:1991;1635-1640.
22. Gold R., Lepow M.L., Goldschneider I., Gotschilich E.C. Immune response of human infants to polysaccharide vaccines of group A and C Neisseria meningitidis. J. Infect. Dis. 136:1977;S31-35.
23. Haase A., Janzen J., Barrett S., Currie B. Toxin production by Burkholderia pseudomallei strains and correlation with severity of melioidosis. J. Med. Microbiol. 46:1997;557563.
24. Haubler S., Nimtz M., Domke T., Wray V., Steinmetz I. Purification and characterization of a cytotoxic exolipid of Burkholderia pseudomallei. Infect. Immun. 66:1998;1588-1593.
25. Heckly R.J. Differentiation of exotoxin and other biologically active substances in Pseudomonas pseudomallei filtrates. J. Bacteriol. 88:1964;1730-1736.
26. Heckly R.J., Nigg C. Toxins of Pseudomonas pseudomallei II. Characterization. J. Bacteriol. 76:1958;427-436.
27. Ho M., Schollaardt T., Smith M.D., Perry M.B., Brett P.J., Chaowagul W., Bryan L.E. Specificity and functional activity of anti-Burkholderia pseudomallei polysaccharide antibodies. Infect. Immun. 65:1997;3648-3653.
28. Hodgkin P.D., Basten A. B cell activation, tolerance and antigen-presenting function. Curr. Opin. Immunol. 7:1995;121-129.
29. Howe C., Sampath A., Spotnitz M. The pseudomallei group: a review. J. Infect. Dis. 124:1971;598-606.
30. Huang C.T. What is Pseudomonas pseudomallei. Elixir. 70:1976;2.
31. Insel R.A., Anderson P. Oligosaccharide-protein conjugate vaccines induce and prime for oligoclonal IgG antibody responses to Haemophilus influenzae b capsular polysaccharide in human infants. J. Exp. Med. 163:1986;262-269.
32. Ismail G., Embi M.N., Omar O., Razak N. Toxigenic properties of Pseudomonas pseudomallei extracellular products. Trop. Biomed. 4:1987;101-110.
33. Ismail G., Razak N., Mohamed R., Embi N., Omar O. Resistance of Pseudomonas pseudomallei to normal human serum bactericidal action. Microbiol. Immunol. 32:1988;645-652.
34. Jennings H. Capsular polysaccharides as human vaccines. Advan. Carbohydr. Chem. 41:1983;155-208.
35. Jennings H. Further approaches for optimizing polysaccharide-protein conjugate vaccines for prevention of invasive bacterial disease. J. Infect. Dis. 165:1992;S156-159.
36. Joiner K.A. Complement evasion by bacteria and parasites. Annul Rev. Microbiol. 42:1988;201-230.
37. Kanai K., Kondo E. Substrate response in acid phosphatase activity of Pseudomonas pseudomallei and Pseudomonas cepacia, with special reference to tyrosine phosphatase. Jpn. J. Med. Sci. Biol. 44:1991;225-237.
38. Kanai K., Kondo E. Recent advances in biomedical sciences of Burkholderia pseudomallei (basonym: Pseudomonas pseudomallei). Jpn. J. Med. Sci. Biol. 47:1994;1-45.
39. Kanai K., Kondo E., Kurata T. Affinity and response of Burkholderia pseudomallei and Burkholderia cepacia to insulin. Asian J. Trop. Med. Public Health. 27:1996;584-591.
40. Ketterer P.J., Bamford V.W. A case of melioidosis in lambs in South Western Australia. Aust. Vet. J. 43:1967;79-80.
41. Knirel Y.A., Paramonov N.A., Shashkov A.S., Kochetkov N.K., Yarullin R.G., Farber S.M., Efremenko V.I. Structure of the polysaccharide chains of Pseudomonas pseudomallei lipopolysaccharides. Carbohydr. Res. 233:1992;185-193.
42. Konadu E., Robbins J.B., Shiloach J., Bryla D.B., Szu S.C. Preparation, charaterization and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccines. Infect. Immun. 62:1994;5048-5054.
43. Kondo E., Kurata T., Naigowit P., Kanai K. Evolution of cell-surface acid phosphatase of Burkholderia pseudomallei. Asian J. Trop. Med. Public Health. 27:1996;592-599.
44. Leelarasamee A., Bovornkitti S. Melioidosis: review and update. Rev. Infect. Dis. 11:1989;413-425.
45. Lett E., Gangloff S., Zimmerman M., Wachsmann D., Klein J.-P. Immunogenicity of polysaccharides conjugated to peptides containing T- and B-cell epitopes. Infect. Immun. 62:1994;785-792.
46. Masoud H., Ho M., Schollaardt T., Perry M.B. Characterization of the capsular polysaccharide of Burkholderia (Pseudomonas) pseudomallei 304b. J. Bacteriol. 179:1997;5663-5669.
47. Mays E.E., Ricketts E.A. Melioidosis: recrudescence associated with bronchogenic carcinoma twenty-six years following initial geographic exposure. Chest. 68:1975;261-263.
48. McCormick J.B., Sexton D.J., McMurray J.G., Carey E., Hayes P., Feldman R.A. Human-to-human transmission of Pseudomonas pseudomallei. Ann. Intern. Med. 83:1975;512-513.
49. Moens S.M., Vanderleyden J. Functions of bacterial flagella. Crit. Rev. Microbiol. 22:1996;67-100.
50. Mond J.J., Vos Q., Lees A., Snapper C.M. T cell independent antigens. Curr. Opin. Immunol. 7:1995;349-354.
51. Nigg C., Heckly R.J., Colling M. Toxin produced by Malleomyces pseudomallei. Proc. Soc. Exp. Biol. Med. 89:1955;17-20.
52. Nimtz M., Wray V., Domke T., Brenneke B., Haussler S., Steinmetz I. Structure of an acidic exopolysaccharide of Burkholderia pseudomallei. Eur. J. Biochem. 250:1997;608-616.
53. Penn C.W., Luke C.J. Bacterial flagellar diversity and significance in pathogenesis. FEMS Microbiol. Lett. 100:1992;331-336.
54. Perry M.B., MacLean L.L., Schollaardt T., Bryan L.E., Ho M. Structural characterization of the lipopolysaccharide O antigens of Burkholderia pseudomallei. Infect. Immun. 63:1995;3348-3352.
55. Pitt T.L., Aucken H., Dance D.A. Homogeneity of lipopolysaccharide antigens in Pseudomonas pseudomallei. J. Infect. 25:1992;139-146.
56. Pruksachartvuthi S., Aswapokee N., Thakerngpol K. Survival of Pseudomonas pseudomallei in human phagocytes. J. Med. Microbiol. 31:1990;109-114.
57. Pugsley A.P. The complete general secretory pathway in Gram-negative bacteria. Microbiol. Rev. 57:1993;50-108.
58. Robbins J.B. Vaccines for the prevention of encapsulated bacterial diseases: current status, problems and prospects for the future. Immunochem. 15:1978;839-853.
59. Sanford J.P. Mandell G.L., Douglas Jr R.G., Bennett J.E. Principles and Practice of Infectious Diseases. 1990;1692-1696 Churchill Livingstone, New York.
60. Sexton M.M., Jones A.L., Chaowagul W., Woods D.E. Purification and characterization of a protease from Pseudomonas pseudomallei. Can. J. Microbiol. 40:1994;903910.
61. Smith C.J., Allen J.C., Embi M.N., Othman O., Razak N., Ismail G. Human melioidosis: and emerging medical problem. MIRCEN J. 3:1987;343-366.
62. Steinmetz I., Rohde M., Brenneke B. Purification and characterization of an exopolysaccharide of Burkholderia (Pseudomonas) pseudomallei. Infect. Immun. 63:1995;39593965.
63. Sutmoller P., Kraneveld F.C., Van Der Schaaf A. Melioidosis (pseudomalleus) in sheep, goats and pigs on Aruba (Netherland Antilles). J. Am. Vet. Med. Assoc. 130:1957;415417.
64. Tanphaichitra D. Tropical disease in the immunocompromised host: melioidosis and pythiosis. Rev. Infect. Dis. 11(Suppl 7):1989;S1629-S1643.
65. Watson D.C., Robbins J.B., Szu S.C. Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein conjugate vaccine. Infect. Immun. 60:1992;4679-4686.
66. Weinberg, A.N., Heller, H.M., 1997. In: Infectious Diseases of the Lung, Thieme-Stratton, New York, pp. 2413-2430.
67. Whitmore A. An account of a glanders-like disease occurring in Rangoon. J. Hyg. 13:1913;135.
68. Whitmore A., Krishnaswami C.S. An account of the discovery of a hitherto undescribed infective disease occurring among the population of Rangoon. Indian Med. Gaz. 47:1912;262-267.
69. Winter A.J., Rowe G.E., Duncan J.R., Eis M.J., Widom B. Effectiveness of natural and synthetic complexes of porin and O-polysaccharide as vaccines against Brucella abortus in mice. Infect. Immun. 56:1988;2808-2817.
70. Woods D.E., Jones A.L., Hill P.J. Interaction of insulin with Pseudomonas pseudomallei. Infect. Immun. 61:1993;4045-4050.
71. Yang H., Kooi C.D., Sokol P.A. Ability of Pseudomonas pseudomallei malleobactin to acquire transferrin-bound, lactoferrin-bound, and cell-derived iron. Infect. Immun. 61:1993;656-662.
72. Yang H.M., Chaowagul W., Sokol P.A. Siderophore production by Pseudomonas pseudomallei. Infect. Immun. 59:1991;776-780.